8-K: Cue Biopharma Inks Collaboration and License Agreement with Boehringer Ingelheim for B Cell Depletion Therapies

Cue Biopharma has entered into a collaboration and license agreement with Boehringer Ingelheim to develop and commercialize B cell depletion molecules, including Cue Biopharma's CUE-501 product candidate.

Summary

• Cue Biopharma has entered into a Collaboration and License Agreement with Boehringer Ingelheim (BI) on April 10, 2025, to develop and commercialize B cell depletion molecules.
• The collaboration includes CUE-501, Cue Biopharma's product candidate for autoimmune diseases.
• The agreement involves collaborative research for four years or until research plans are completed.
• BI may include additional or alternative compounds targeted at B cell depletion.
• BI receives an exclusive, worldwide license to develop, manufacture, and commercialize these compounds.
• BI will handle all further research, development, manufacturing, regulatory approvals, and commercialization at its expense.
• Cue Biopharma is restricted from developing or commercializing any molecule for B cell depletion during the Research Term.
• Cue Biopharma will receive an upfront payment of $12.0 million.
• Cue Biopharma is eligible for up to $345.0 million in success-based milestone payments, starting with preclinical development milestones.
• Cue Biopharma will also receive royalty payments on net sales, subject to reductions for patent expiration, third-party IP licenses, and generic competition.
• BI will make research support payments to Cue Biopharma during the Research Term.
• The agreement continues until the expiration of the royalty term on a product-by-product and country-by-country basis, unless terminated earlier.
• BI can terminate the agreement for any reason after a specified notice period.
• Either party can terminate the agreement due to bankruptcy or material breach by the other party.
• Cue Biopharma also amended its license agreement with Albert Einstein College of Medicine to allow the sublicense to BI.

Sentiment

Score: 8

Explanation: The agreement with Boehringer Ingelheim is a positive development for Cue Biopharma, providing significant funding and validation of its technology. The potential for substantial milestone and royalty payments suggests a favorable outlook.

Positives

• The collaboration provides Cue Biopharma with significant funding, including a $12.0 million upfront payment.
• The potential for $345.0 million in milestone payments offers substantial future revenue.
• Boehringer Ingelheim will bear the costs of further development, manufacturing, and commercialization, reducing Cue Biopharma's financial burden.
• The agreement validates Cue Biopharma's technology and its potential in autoimmune disease treatment.
• The amendment to the Einstein license agreement removes a potential obstacle to the collaboration.

Negatives

• Cue Biopharma is restricted from developing or commercializing any molecule for B cell depletion during the Research Term, limiting its independent activities in this area.
• Royalty payments are subject to reduction due to patent expiration, third-party IP licenses, and generic competition, which could impact long-term revenue.
• Boehringer Ingelheim has the right to terminate the agreement for any reason after a specified notice period, creating uncertainty for Cue Biopharma.

Risks

• The success of the collaboration depends on the successful development and commercialization of the licensed products by Boehringer Ingelheim.
• The receipt of milestone payments is contingent on achieving specific research, development, and commercial milestones.
• Patent expiration, third-party IP licenses, and generic competition could reduce royalty payments.
• Boehringer Ingelheim's right to terminate the agreement could disrupt Cue Biopharma's plans.
• The collaboration may face unforeseen challenges in research, development, or regulatory approval.

Future Outlook

The collaboration aims to develop and commercialize differentiated B cell depletion molecules, with Boehringer Ingelheim leading further development and commercialization efforts. Cue Biopharma is positioned to receive significant milestone and royalty payments upon successful development and commercialization.

Management Comments

• There are no direct management quotes in the document, but the signing of the agreement suggests a positive outlook from management regarding the collaboration's potential.

Industry Context

This agreement reflects a growing trend in the pharmaceutical industry towards collaboration and licensing agreements to leverage expertise and share the risks and costs of drug development. B cell depletion therapies are an area of active research for autoimmune diseases, making this a potentially lucrative market.

Comparison to Industry Standards

• Collaboration agreements in the biotech industry often involve upfront payments, milestone payments, and royalties, similar to the structure of this agreement.
• Upfront payments of $12 million are within the typical range for early-stage collaborations, but the potential for $345 million in milestone payments suggests significant confidence in the technology.
• Companies like AbbVie, Roche, and Bristol Myers Squibb have also engaged in similar collaborations to expand their pipelines and access innovative technologies.
• The specific terms of the agreement, such as royalty rates and milestone criteria, would need to be compared to similar deals to assess its competitiveness.

Stakeholder Impact

• Shareholders will likely react positively to the news of the collaboration and the potential for future revenue.
• Employees may benefit from increased job security and opportunities for growth.
• Patients with autoimmune diseases may benefit from the development of new B cell depletion therapies.
• The collaboration could strengthen Cue Biopharma's relationships with suppliers and partners.

Next Steps

• Boehringer Ingelheim will conduct further research, preclinical and clinical development, manufacturing, regulatory approvals, and commercialization of the licensed products.
• Cue Biopharma will collaborate with Boehringer Ingelheim during the Research Term.
• Cue Biopharma will file the Collaboration and License Agreement and the Amendment to the Einstein License Agreement as exhibits to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.

Key Dates

Keywords

Collaboration, License Agreement, Boehringer Ingelheim, Cue Biopharma, B Cell Depletion, CUE-501, Autoimmune Diseases, Pharmaceuticals, Biotechnology